Human growth hormone

In MONARCH 2 ( M2 ), Abemaciclib ( Verzenios ), an oral selective cyclin dependent kinase 4 & 6 inhibitor,...


Abemaciclib ( Verzenio ) in combination with standard adjuvant endocrine therapy has met the primary endpoint of invasive disease-free...


The FDA ( U.S. Food and Drug Administration ) has warned that Ibrance ( Palbociclib ), Kisqali ( Ribociclib ),...


Abemaciclib ( Verzenios ) is an oral, selective cyclin-dependent kinase 4 & 6 inhibitor, approved for hormone receptor-positive ( HR+...


The FDA ( U.S. Food and Drug Administration ) has extended the indication of Ibrance ( Palbociclib ) capsules in...


The FDA ( U.S. Food and Drug Administration ) has approved Piqray ( Alpelisib ) tablets, to be used in...


The European Commission has approved Talzenna ( Talazoparib ), an oral poly (ADP-ribose) polymerase ( PARP ) inhibitor, as monotherapy...


The results of a pediatric phase 2 clinical trial of Burosumab ( Crysvita ) for the treatment of X-linked hypophosphatemia...


Results of the global phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor Alpelisib ( BYL719 ) has met...


The FDA ( US Food and Drug Administration ) has approved Kisqali ( Ribociclib ) for women with hormone-receptor positive,...


The European Medicines Agency ( EMA ) has recommended granting a marketing authorisation to Jinarc ( Tolvaptan ). Jinarc is...


The aim of American Society of Clinical Oncology ( ASCO ) Clinical Practice Guideline is to provide evidence-based recommendations to...


Pfizer has announced that the randomized Phase 2 trial, PALOMA-1, of Palbociclib achieved its primary endpoint by demonstrating a statistically...


Patients with breast cancer are classified as having cells that over-express the human epidermal growth factor receptor 2 ( known...


Data from a pooled analysis presented today at the 50th Annual Meeting of the American Society of Clinical Oncology (...


Melbourne researchers have discovered that anti-cancer compounds currently in clinical trials for some types of leukaemia could offer hope for...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion, recommending the granting of...


A new osteoporosis drug hinders the growth of estrogen-sensitive cancer that has become resistant to treatment with tamoxifen, a study...


Halaven ( Eribulin mesylate ), a non-taxane, microtubule dynamics inhibitor with a novel mechanism of action, belongs to a class...


The results of a phase III study ( Study 301 ) of Eribulin mesylate ( Halaven ) versus Capecitabine (...